Related Experiment Video
Updated: Sep 9, 2025
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4
Mayuka Fukata1, Tomomi Omura2, Keiko Maeda2
1Department of Residency Training, Meitetsu Hospital, Nagoya, JPN.
Abstract:
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for the treatment of type 2 diabetes mellitus. Recently, their association with drug-induced bullous pemphigoid (BP) has attracted increasing attention. In this report, we present a case of an 84-year-old woman who developed BP after COVID-19 infection while taking a DPP-4 inhibitor. The temporal relationship between drug administration, viral infection, and onset of autoimmune disease indicates a possible interaction between COVID-19-induced immune dysregulation and DPP-4 inhibition. The coexistence of these factors may increase the risk of developing BP in older patients with diabetes, which warrants careful monitoring.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...